Lucas, Claire M., Scott, Laura J., Carmell, Natasha, Holcroft, Alison K., Hills, Robert K.  ORCID: https://orcid.org/0000-0003-0166-0062, Burnett, Alan K. and Clark, Richard E.
2018.
CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.
Blood Advances
2
(9)
, p. 964.
10.1182/bloodadvances.2017013615
|
Preview |
PDF
- Published Version
Download (812kB) | Preview |
Official URL: http://dx.doi.org/10.1182/bloodadvances.2017013615
Abstract
PP2A inhibition occurs in AML by 2 different pathways: CIP2A in normal karyotype patients and SETBP1 in adverse karyotype patients. AKTS473 phosphorylation is a predictor of survival, and diagnostic levels of AKTS473 could be a novel biomarker in AML.
| Item Type: | Article |
|---|---|
| Date Type: | Published Online |
| Status: | Published |
| Schools: | Schools > Medicine |
| Publisher: | American Society of Hematology: Blood Advances |
| ISSN: | 2473-9529 |
| Date of First Compliant Deposit: | 3 August 2018 |
| Date of Acceptance: | 16 March 2018 |
| Last Modified: | 05 May 2023 06:43 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/113883 |
Citation Data
Cited 11 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Dimensions
Dimensions